FCFS vs CORT
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
FCFS · FirstCash$185.67 ▼ 1.00%
CORT · Corcept Therapeutics$72.77 ▲ 1.59%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- FCFS +16.1%
- CORT -3.6%
Head to head
| Metric | FCFS | CORT |
|---|---|---|
| Price | $185.67 | $72.77 |
| Change today | ▼ 1.00% | ▲ 1.59% |
| Market cap | $7.96B | $7.96B |
| Return, 3 months | -10.9% | -36.3% |
| Return, year to date | +17.2% | +109.1% |
| Return, 1 year | +16.5% | -1.3% |
| P/E (TTM) | 20.1 | 54.7 |
| P/B | 3.5 | 9.6 |
| P/E percentile vs own 5y | 17th | 74th |
| Dividend yield | 0.90% | – |
| Revenue growth (YoY, latest qtr) | +17.7% | +31.7% |
| Net profit growth (YoY) | +22.2% | +22.3% |
| Gross margin | 50.2% | 98.3% |
| Operating margin | 16.1% | 0.8% |
| Net margin | 9.5% | 6.5% |
| Return on equity | 18.2% | 8.1% |
| Analyst target vs. price | +32.9% | +127.8% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 39 | 22 |
| 30-day volatility | 60.3% | 79.8% |
| Max drawdown, 1 year | -26.9% | -63.5% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- CORT is the largest of the group by market value.
- FCFS has returned the most over the past year.
- FCFS carries the lowest trailing P/E.
- CORT is growing revenue fastest.
- FCFS keeps the most profit per dollar of sales.
- FCFS has been the calmest stock over the last 30 days.